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Abstract
Background: Several classifications of adult asthma patients using cluster analyses based on clinical and
demographic information has resulted in clinical phenotypic clusters that do not address molecular mechanisms.
Volatile organic compounds (VOC) in exhaled air are released during inflammation in response to oxidative stress as
a result of activated leukocytes. VOC profiles in exhaled air could distinguish between asthma patients and healthy
subjects. In this study, we aimed to classify new asthma endotypes by combining inflammatory mechanisms
investigated by VOC profiles in exhaled air and clinical information of asthma patients.
Methods: Breath samples were analyzed for VOC profiles by gas chromatography–mass spectrometry from asthma
patients (n = 195) and healthy controls (n = 40). A total of 945 determined compounds were subjected to
discriminant analysis to find those that could discriminate healthy from asthmatic subjects. 2-step cluster analysis
based on clinical information and VOCs in exhaled air were used to form asthma endotypes.
Results: We identified 16 VOCs, which could distinguish between healthy and asthma subjects with a sensitivity
of 100% and a specificity of 91.1%. Cluster analysis based on VOCs in exhaled air and the clinical parameters
FEV1, FEV1 change after 3 weeks of hospitalization, allergic sensitization, Junipers symptoms score and asthma
medications resulted in the formation of 7 different asthma endotype clusters. We identified asthma clusters with
different VOC profiles but similar clinical characteristics and endotypes with similar VOC profiles, but distinct clinical
characteristics.
Conclusion: This study demonstrates that both, clinical presentation of asthma and inflammatory mechanisms in
the airways should be considered for classification of asthma subtypes.
Keywords: Asthma, Endotypes, Phenotype, Volatile organic compounds, Exhaled air, Cluster
Background
Asthma is a chronic inflammatory disorder of the airways,
which causes typical clinical symptoms like wheezing,
breathlessness and chest tightness associated with a rever-
sible obstruction of the airways. The heterogeneity of the
clinical dimensions of asthma lead to the definition of
clinical asthma phenotypes, classified by steroid response,
obesity, fixed airway obstruction or trigger factors like
allergens, air pollution, cigarette smoke, aspirin and exer-
cise [1]. Using cluster analyses based on clinical and de-
mographic information, adult asthma patients could be
classified into 5 different subgroups [2], and children with
severe asthma could be divided into 4 phenotypic clusters
[3]. It is assumed that the clinical asthma phenotypes
are associated with different inflammatory pathways
or molecular mechanisms and on the other hand, similar
molecular mechanisms may be present in different asthma
phenotypes. In this context, the term “asthma endotypes”
was introduced. Endotypes describe disease entities, which
are functionally defined by distinct clinical features and
pathologically by a molecular mechanism and treatment
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response [4,5]. It is proposed that the classification of pa-
tients into endotypes is important for establishing effective
preventive measures and determining appropriate indi-
vidualized treatments [1]. For quantification of molecular
mechanisms non-invasive methods, reflecting the local
airway inflammation, are important approaches.
Analysis of volatile organic compounds (VOC) in ex-
haled breath is a useful and non-invasive method for the
assessment of airway inflammation [6]. For the collection
of exhaled breath, three to four normal exhalations are
necessary, which could be easily performed in children or
in severe asthma patients with very low expiratory vol-
umes [7]. VOCs are present in ambient air as well as result
from metabolic processes in many cells and microorgan-
isms. They are mainly released during inflammation from
cells in response to oxidative stress as a result of activated
leukocytes, which produce reactive oxygen species (ROS)
[8]. ROS degrade cell membranes by lipid peroxidation
and convert polyunsaturated fatty acids to VOCs, which
are exhaled in the breath. In the human breath hundreds
of different VOCs can be detected, which are divided into
hydrocarbons, oxygen, or sulfur containing compounds
and nitrogen containing substances [9]. The relative com-
position and concentrations of VOCs may alter in the
presence of diseases and characteristic VOC patterns in
lung diseases like lung cancer [10], cystic fibrosis [11],
chronic obstructive pulmonary disease [12] and asthma
[7] have been demonstrated. VOC profiles in exhaled air
may distinguish between asthma patients and patients with
chronic obstructive pulmonary disease [13]. In asthma
patients, VOC patterns have been identified, which could
specifically distinguish between allergic and non-allergic
asthma [7] suggesting that different asthma phenotypes
may be characterized by different VOC profiles in exhaled
air. In addition, a recent study demonstrate that VOC pro-
files in exhaled air could classify clinically relevant disease
phenotypes based on sputum inflammatory profile [14]
and that VOC profiles might predict steroid responsive-
ness in mild/moderate asthma patients [15].
In this study, we measured VOCs in exhaled air from
asthma patients and used the VOC profiles together with
clinical characteristics for the formation of asthma clus-
ters. We wanted to test the hypothesis that asthma clus-
ters with similar clinical characteristics but different VOC
patterns in exhaled air or clusters with similar VOC pat-
terns but different clinical characteristics exist.
Methods
Study design and asthma patients
Adult patients had a physician diagnosis of asthma ac-
cording to GINA guidelines (Global Initiative for Asthma,
www.ginasthma.org). All patients included in the study
were treated for at least 3 weeks at the high altitude clinic
Davos-Wolfgang, which is located at 1600 m above sea
level in the Swiss Alpine. The clinical and examination pa-
rameters were assessed when the patient arrived and after
3 weeks. All patients were recruited during a period of
8 months. The asthma patients were admitted to the high
altitude clinic to optimize their disease. Therefore, mild,
moderate and severe asthma patients were included. To
exclude chronic obstructive pulmonary disease, asthma
was defined by a reversibility in forced expiratory volume
in 1 s (FEV1) of at least 12% predicted after inhalation of a
short acting β2-agonist. Asthma patients with an acute
respiratory infection were excluded. To classify these
patients as atopic or non-atopic, we evaluated their
medical history, and skin prick tests were performed
with animal dander, food allergens, pollens, fungi and
latex. The NIOX system from Aerocrine was used for
FENO (exhaled nitric oxide) measurements, according
to the manufacturer’s instructions. Blood eosinophils and
eosininophilic cationic protein (ECP) were analysed in the
laboratory of the high altitude clinic. The multidisciplinary
treatment at high altitude, consisting of personalised treat-
ment plans with physiotherapy and education, aimed to
achieve full asthma control with the lowest possible dose
of asthma medication. For the assessment of the level of
asthma control the six-item Asthma Control Question-
naire (Junipers symptom score) was used [16]. Responses
to each item are rated on a six-point scale and sub-
sequently the mean was calculated, which ranged between
0 (totally controlled) and 6 (severely uncontrolled). Infor-
med consent was obtained from all asthma patients. The
main characteristics of the asthma patients are shown
in Table 1. The study was approved by the local ethical
committees of Graubünden and of Zürich. The data was
stored in a database and analyzed by SPSS 18 (SPSS
Schweiz AG, Zürich, Switzerland) and Graphpad Prism 4
(Graphprism Software, La Jolla, California). Healthy con-
trols living in Davos were selected without any diseases
and no allergies in their history during the same period of
the study.
Collection of exhaled air
Exhaled air was collected between 07.00 and 07.30 h
from all asthma patients and healthy subjects before
breakfast. The subjects were asked to exhale their breath
in a resistance-free plastic bag (Tedlar bag, SKC Ltd,
Dorset, UK). Three to four exhalations were sufficient to
fill the 5 l bag. No special provisions for the mode of
exhalation, nor special directions concerning the diet of
the subjects were given. The samples of both patients
and controls were collected in the same room, to prevent
the occurrence of a background bias. Therefore, and be-
cause of the data analysis methods used (i.e. discrimin-
ant analysis), no background samples were collected.
Within 1 h of collection, the bag was emptied under
pressure over a stainless-steel two-bed sorption tube,
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filled with carbograph 1TD/Carbopack X (Markes Inter-
national, Llantrisant, Wales, UK) and stored at room
temperature until analysis.
VOC’s analysis
For the analyses, the desorption tubes were placed inside
the thermal desorption unit (Marks Unity desorption
unit, Marks International Limited, Llantrisant, Wales,
UK) and quickly heated to 270°C in order to release all
VOCs and transport the released VOCs onto the GC-
capillary. The used desorption unit was highly suitable
for repeated, quantitative and reproducible measure-
ments. Ten percent of the sample was injected into the
GC, the remaining 90% transported to another adsorption
tube for storage and any later re-analysis. Just before the
sample enters the GC, the sample is trapped by a cold trap
at 5°C in order to focus and concentrate the sample. The
VOCs were separated by capillary gas chromatography
(column: RTX-5 ms, 30 m × 0.25 mm 5% diphenyl, 95%
dimethylsiloxane, film thickness 1 μm, Thermo Electron
Trace GC Ultra, Thermo Electron Corporation, Waltham,
USA). The temperature of the gas chromatograph was
programmed as follows: 40°C during 5 min, then raised
with 10°C/min until a final maximum temperature of
270°C. This temperature was maintained for 5 min.
Time-of-flight mass spectrometry (TOF-MS) (Thermo
Electron Tempus Plus time-of-flight mass spectrometer,
Thermo Electron Corporation, Waltham, USA) was
used to detect and identify components available in the
samples. Electron ionization mode was set at 70 eV and
the mass range m/z 35–350 was measured at a scan rate
of 0.2 s. All chromatograms were preprocessed [6] and
combined into a final data matrix, which was used for the
discriminant analyses.
Cluster formation and statistical analyses
Variables for cluster analyses were selected on the basis of
their considered contribution for the characterization of
asthma endotypes. Categorical variables were standardized
to 0 or 1 and continuous variables were standardized to a
continuous scale between 0 and 1. For cluster analysis of
categorical and continuous variables 2-step cluster ana-
lysis approach using the program IBM SPSS Statistics 18.0
(IBM Corporation, New York, United States) was per-
formed. To avoid the formation of very small clusters, the
maximum cluster number was limited to 8. Mean values
of examination results or clinical features were calculated
and are shown as mean ± standard deviation (SD). All stat-
istical analyses were performed using SPSS version 18.0
(IBM) and Graph Prism version 4.0 (GraphPad Software
Inc, San Diego, CA).
Results
Identification of VOCs implicated in the pathogenesis of
asthma
To investigate, which VOCs are implicated during asth-
matic airway inflammation, VOCs in exhaled air were
compared between asthma patients and healthy controls.
A total of 945 VOCs were found. To select the most rele-
vant VOCs, a classification model was constructed based
on 16 VOCs. With this model it was possible to distin-
guish between asthma patients and healthy controls with
a sensitivity of 100% and specificity of 91.1% if 16 compo-
nents were used. 5 components were still sufficient to
achieve a sensitivity of 100% and specificity of 85.3%
(Figure 1A). This model with 16 VOCs was able to clas-
sify healthy and asthma subjects 98.7% correctly. The
model with 5 VOCs still classified the subjects 98.0%
correctly (Figure 1B). The chemical structures of the
VOCs were partly identified and are shown (Additional
file 1: Table S1).
Formation of asthma endotypes
For the formation of asthma endotype clusters by clin-
ical features, asthma medications and VOCs in exhaled
air unsupervised hierarchical two-step cluster analysis
was used. The clinical features included forced expiratory
volume in one-second (FEV1), its ratio to the inspiratory
vital capacity (IVC), FEV1 improvement after 3 weeks in
the high altitude clinic and Junipers asthma symptom
score assessed at admittance. The therapy features inclu-
ded the fraction of patients using systemic steroids,
inhaled steroids or long β2 agonists and the frequency of
Table 1 Characteristics of asthma patients
Allergic asthma 77.9%
Age (years) 49.8 ± 15.2
Age of onset (years) 23.5 ± 17.0
Gender (male) 44.6%
Smoker 4.6%
Long-acting β2 agonist 92.8%
Short-acting β2 agonist (puffs per day) 1.8 ± 3.2
Systemic steroids 26.1%
Inhaled steroids 94.9%
Theophylline 21.0%
Junipers symptoms score 2.2 ± 1.2
ATS 30.2%
Serum ECP (μg/l) 22.9 ± 18.6
Blood eosinophils (%) 5.6 ± 3.8
FEV1 (% of predicted normal value) 83.2 ± 23.5
Percentages of male asthma patients, asthma patients who are active smokers,
asthma patients fulfilling ATS (American Thoracic Society) criterias for severe
asthma, asthma patients with an allergic asthma and asthma patients with
theophylline, inhaled long acting β2 agonists, inhaled steroids or systemic
steroids as treatment are shown. In addition, year of onset, age, serum ECP
(eosinophilic cationic protein), blood eosinophils, FEV1 values are shown. The
units are indicated in the brackets.
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short β2 agonist usage per day. To have an equal propor-
tion between clinical parameters, asthma therapy features
and VOCs in exhaled air for cluster analysis, we selected
4 VOCs for cluster analysis, which were detectable in
asthma but not in healthy subjects (Figure 2). In detail,
VOCs 141, 424, 470, 478 were selected (Figure 2A).
Unsupervised hierarchical two-step cluster analysis
of clinical features, asthma medications and 4 VOCs di-
vided the asthma patients into 7 different clusters (Table 2).
The two smallest clusters included 14 patients (cluster 4
and 7) and the largest cluster 40 patients (cluster 2).
Asthma patients in cluster 6 and 7 have a non-allergic
asthma. The asthma patients of cluster 7 have a more
severe disease compared to the asthma patients in cluster
6. In detail, asthma patients in cluster 7 have all systemic
steroids as medications, a lower FEV1 and higher asthma
symptoms scores compared to asthma patients in cluster
6 (Table 2).
In addition, 5 subgroups of patients with an allergic
asthma were identified (cluster 1–5). Asthma patients in
cluster 3 showed the most severe disease of allergic
asthma with a high Junipers symptoms score, a low FEV1
but patients in cluster 3 did not use systemic steroids for
asthma therapy. Asthma patients in clusters 1 and 2 had
similar clinical features, including good FEV1 values, low
Junipers symptoms scores, and no systemic steroid usage
as asthma medications. Asthma patients in cluster 4 have
a mild allergic asthma with similar clinical characteristics
like asthma patients in cluster 1 and 2 but receive different
asthma medications. Cluster 5 identifies asthma patients
with a moderate allergic asthma having systemic steroids
as asthma medication (for more details see Table 2).
More clinical and demographic parameters including
age of onset, gender, body mass index (BMI), smoking
habits, American thorax society (ATS) criteria for severe
asthma, exhaled nitric oxide, serum eosinophilic cationic
protein (ECP), circulating eosinophils, IgE serum levels,
and usage of theophylline, which were not used for the
cluster analysis, are shown in Table 3.
Characterization of VOC profiles in asthma endotypes
The concentrations of VOCs in the asthma clusters are
shown in Table 2. To investigate if the VOCs were different
or similar in the identified asthma clusters, we analysed if
the VOCs could discriminate between them. Linear dis-
criminant analysis demonstrates that 42.8% of all asthma
patient clusters and healthy subjects could be correctly
classified by VOCs in the exhaled air (Figure 3A). However,
the correct classification was different between the clusters
indicating that there exist clusters with similar VOC pro-
files and clusters with different VOC profiles. Subsequent
analyses demonstrate that cluster 1 and 2 have similar
clinical features (Table 2) but different VOC patterns in
exhaled air (Figure 3B). Profiles of VOCs can discriminate
between cluster 1, 2 and healthy subjects with an high
accuracy of 95.3% (Figure 3B). In contrast, the correct clas-
sification of asthma patients belonging to cluster 6 and 7
and healthy donors was only 81.8% and there was much
overlap of the VOC patterns between these clusters indi-
cating that these asthma clusters have similar VOC pat-
terns in exhaled air (Figure 3C). Interestingly, asthma
patients belonging to cluster 6 and 7 have distinct clinical
and treatment characteristics (see Table 2). Similar results
were found for cluster 3 and 4 (Figure 3D), which are
clinical different but have a quite related profile of VOCs
in exhaled air as indicated by the relatively low accuracy
of 82.9% to distinguish between the asthma patients
clusters and healthy donors.
In addition, a second possibility of cluster analysis was
performed. In this data set, the following additional pa-
rameters were included: age of onset, blood eosinophils,
body mass index (BMI), serum IgE levels, exhaled nitric
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Figure 1 Course of sensitivity and specificity as a function of the number of VOCs involved in the discriminant analyses. The sensitivity
and specificity to discriminate between asthma and healthy subjects depends on the number of VOCs (A). The correct classification of asthma
and healthy subjects as a function of the VOCs is presented (B).
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Figure 2 VOC concentrations in exhaled air in asthma patients and healthy subjects. VOC in exhaled air were compared between healthy
donors and asthma patients. The four VOCs, which have been selected for cluster analyses, are shown in A. VOCs not selected for cluster analyses
are shown in B.
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oxide (FeNO) and asthma control. Because unsupervised
cluster resulted in the formation of only 3 clusters, a 2-
step cluster analysis of this data set using a user-defined
cluster number of 7 was performed. We have detected
two clusters with a non-allergic asthma and 5 clusters
with an allergic asthma (see Additional file 1: Table S2).
Again, clusters with a high clinical similarity but distinct
profiles of exhaled VOCs (e.g. cluster 2 and 3, Additional
file 1: Figure S1B) and clusters with similar VOCs pat-
terns in exhaled air but distinct clinical and treatment
characteristics (e.g. clusters 2 and 4, Additional file 1:
Figure S1C) are present. Interestingly, cluster 2 and 3 have
not only distinct VOCs profiles, they also differ in total
IgE levels and blood eosinophils. In contrast, patients in
cluster 2 and 4 are clinical different and have similar VOC
profiles and IgE/blood eosinophil levels.
Discussion
The current study identifies VOCs in exhaled air, which
could distinguish between asthma patients and healthy
subjects with a sensitivity of 100% and specificity of 91%.
The combination of clinical asthma features, asthma
therapy and exhaled VOCs classified asthma patients
into 7 endotype clusters. We identified asthma clusters
Table 2 Values for cluster formation
Parameter Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6 Cluster 7
n 33 40 28 14 37 29 14
Allergies 100% 100% 100% 100% 100% 0% 0%
FEV1 99.7 ± 15.8 96.7 ± 16.3 58.7 ± 14.5 105.0 ± 17.2 73.1 ± 18.0 84.4 ± 18.1 58.3 ± 22.5
FEV1/IVC 0.99 ± 0.09 0.98 ± 0.1 0.77 ± 0.15 1.02 ± 0.05 0.91 ± 0.18 0.92 ± 0.17 0.71 ± 0.21
FEV1 improvement −4.9 ± 11.8 1.3 ± 7.6 8.6 ± 14.6 −0.4 ± 6.9 2.1 ± 14.0 1.0 ± 11.3 14.8 ± 21.3
Junipere 1.8 ± 1.3 1.6 ± 1.0 3.2 ± 0.8 0.9 ± 0.6 2.8 ± 1.0 1.7 ± 0.9 2.9 ± 1.1
Systemic steroids 0% 0% 0% 7.1% 97.3% 0% 100%
Inhaled steroids 100% 100% 100% 42.9% 100% 96.6% 92.9%
Long β2 mimetics 100% 100% 100% 0% 100% 100% 100%
Short β2 mimetics 0.52 ± 0.94 0.68 ± 1.25 3.93 ± 4.74 0.57 ± 1.40 3.05 ± 3.54 1.10 ± 1.76 3.79 ± 5.32
VOC_141 0.015 ± 0.069 0.191 ± 0.246 0.042 ± 0.119 0.020 ± 0.076 0.163 ± 0.381 0.056 ± 0.165 0.034 ± 0.112
VOC_470 0.033 ± 0.090 0.360 ± 0.253 0.238 ± 0.241 0.126 ± 0.228 0.062 ± 0.143 0.214 ± 0.268 0.174 ± 0.251
VOC_478 0 0.152 ± 0.175 0.041 ± 0.112 0.012 ± 0.046 0.053 ± 0.128 0.104 ± 0.179 0.147 ± 0.195
VOC_424 0.436 ± 0.988 3.228 ± 1.751 1.070 ± 1.654 1.938 ± 1.717 0.933 ± 1.502 1.921 ± 2.031 1.816 ± 1.828
Percentages of patients with allergies, systemic steroids, inhaled steroids and inhaled long acting β2 agonists for asthma treatment are shown. FEV1 (forced expiratory
volume in 1 second) values are shown in the percentage of the predicted normal values for FEV1. For the Junipers symptoms score and short β2 agonists the mean
values ± SD are indicated. Unit for inhalation of short β2 agonists is puffs per day.
Table 3 Additional clinical characteristics of asthma clusters
Parameter Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6 Cluster 7 n
Age of onset (years) 20.7 ± 16.3 19.5 ± 15.4 19.0 ± 17.9 26.5 ± 20.5 24.1 ± 17.1 28.9 ± 14.8 34.3 ± 16.2 195
Gender (male) 36.4% 52.5% 60.1% 35.7% 37.8% 51.7% 21.4% 195
Age 41.6 ± 15.9 46.4 ± 15.9 56.6 ± 12.1 47.3 ± 14.6 49.5 ± 13.4 54.4 ± 12.4 58.9 ± 16.4 195
BMI 25.0 ± 3.6 25.5 ± 3.1 26.0 ± 4.3 25.9 ± 4.2 25.3 ± 4.7 24.7 ± 3.8 24.7 ± 5.0 195
Tobacco exposure (py) 4.2 ± 6.0 3.3 ± 7.7 6.0 ± 8.0 1.8 ± 4.1 4.2 ± 7.1 5.0 ± 8.6 2.0 ± 3.8 195
Smoker 6.1% 2.5% 7.1% 7.1% 5.4% 3.5% 0% 195
ATS 9.1% 12.5% 35.7% 0% 75.7% 6.9% 78.6% 195
Exhaled NO (ppb) 36 ± 29 32 ± 18 34 ± 30 27 ± 27 43 ± 36 28 ± 18 41 ± 26 195
ECP 27.0 ± 27.0 21.7 ± 13.8 26.2 ± 20.8 11.9 ± 7.2 22.3 ± 16.1 18.9 ± 15.6 31.1 ± 19.8 194
Eosinophils 6.5 ± 4.5 5.6 ± 3.1 6.3 ± 3.6 4.8 ± 5.0 4.8 ± 3.1 4.8 ± 3.8 7.2 ± 4.2 195
IgE 1383 ± 4731 524 ± 883 648 ± 1007 304 ± 340 392 ± 877 80 ± 103 140 ± 262 194
Theophyllin 12.1% 12.5% 32.1% 0% 32.4% 10.3% 57.1% 195
Percentages of male asthma patients, asthma patients who are active smokers, asthma patients fulfilling ATS (American Thoracic Society) criterias for severe asthma and
asthma patients with theophylline treatment are shown. In addition, the BMI (body mass index), year of onset, age, exhaled NO (nitric oxide), serum ECP (eosinophilic
cationic protein), blood eosinophils, IgE serum levels are shown as mean values ± SD. The units are indicated in the brackets. Lifetime tobacco exposure is indicated in
pack years (py).
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with different VOC profiles but similar clinical characte-
ristics and clusters with similar VOC profiles, but distinct
clinical characteristics.
The activation of different cellular and molecular path-
ways by different environmental factors suggests that
asthma phenotypes are associated with certain inflam-
matory pathways in the lungs. Asthma endotypes classify
asthma patients according to clinical features, treatment
response and underlying molecular mechanisms and
therefore address molecular mechanism [4]. Accordingly,
we used 13 parameters of clinical features, asthma treat-
ment features and VOCs in exhaled air for cluster analysis
and classified all asthma patients into 7 different clusters.
Recent phenotype studies of severe adult asthma patients
or asthmatic children identified 4–5 asthma groups by
cluster analysis without addressing molecular mechanisms
or including exhaled VOCs for cluster analyses [2,3]. The
identification of asthma patient clusters with similar
clinical and treatment characteristics but different VOC
profiles in the exhaled air indicates that asthma phe-
notypes might be further divided into subgroups by their
exhaled VOC profiles. This finding supports the hypothesis
that one asthma phenotype might be characterized by
several inflammatory mechanisms [5]. The identification
of molecular mechanisms specific for asthma endotypes
and diagnostic biomarkers that can discriminate between
distinct disease endotypes will be necessary for the devel-
opment of new asthma therapies [17]. We also detected
asthma clusters with similar VOC patterns in the exhaled
air but different clinical features suggesting that these
VOCs profiles may be specific for airway inflammation,
which is found in many asthma phenotypes.
In this study VOCs in exhaled air were analysed for
the assessment of airway inflammation because VOCs
mostly derive from biological processes such as lipid per-
oxidation. Pathologic processes have the potential to influ-
ence VOCs either by producing new volatile substances or
by the metabolic consumption of VOC substrates that are
normally present. Volatile products formed during lipid
peroxidation include ethane, pentane, hexanal, octanal,
nonanal, propanol and butanol [18,19]. Already in the
early 80s, pentane and ethane levels in exhaled air were
described as markers for in vivo peroxidation [8]. Ethane
was described to be elevated in the breath of patients with
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Figure 3 Discriminant analyses for asthma clusters. Discrimination analyses between all asthma clusters and healthy patients (A) and
between indicated asthma subgroups (B, C, D) are shown. The percentage indicates the correct classification. Clusters shown in B have similar
phenotype characteristics whereas clusters shown in C and D have different phenotype characteristics (see Table 2).
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chronic obstructive pulmonary disease (COPD) and asthma
[20,21]. However, measuring a single compound in exhaled
air might not be sufficient to monitor complex and het-
erogeneous diseases. In addition, some VOCs in exhaled
air are not only increased during airway inflammation. For
example, pentane appears to be relatively non-specific
VOC for airway inflammation because its levels are also
raised in other inflammatory conditions such as inflam-
matory bowel disease [22] or rheumatoid arthritis [23].
Exploring the total amount of VOCs is expected to ge-
nerate more adequate information about the complexity
of processes underlying the pathophysiology of respiratory
diseases [24]. In our study the most important 16 VOCs
could distinguish with a high sensitivity and specificity
between healthy and asthmatic subjects indicating that the
VOCs are useful for non-invasive exploration of various
biochemical pathways activated in asthma.
Certain inflammatory processes may reflect the involve-
ment of different inflammatory sputum cells. Thus, it has
been demonstrated that VOC profiles in exhaled air could
classify clinically relevant disease phenotypes based on
sputum inflammatory profiles by predicting both neutro-
philic and eosinophilic sputum cell phenotypes of asthma
patients [14]. However, a variety of interactions among
distinct populations of stromal cells, epithelial cells and
leukocytes contribute to inflammation in the asthmatic
lung [25] and may not be assessed by characterization of
cells derived from sputa. Analysis of gene expression in
asthmatic biopsies might be a useful technique to under-
stand the inflammatory processes implicated in airway
inflammation [26,27]. However, obtaining lung biopsies is
invasive and cannot be assessed in all asthma patients. In
contrast, breath analysis could detect VOC profiles in a
non-invasive and straightforward way.
Although this study does not identify VOCs, which in-
dicate specific inflammatory mechanisms in the airways,
we demonstrate that VOCs patterns are an attractive ap-
proach for the classification of asthma patients as they
might reflect inflammatory processes in the airways and
could be collected easily in a non-invasive way. If we
include biological relevant features of blood analyses
like blood eosinophils and IgE serum levels into the
cluster analyses, we detect clusters having similar clinical
asthma features (see Additional file 1: Table S2) but
differ in IgE levels, blood eosinophils and VOCs sug-
gesting that certain VOCs profiles might indicate IgE-
and eosinophil-mediated inflammation. The identification
of VOCs as markers for certain inflammatory path-
ways in asthma patients (e.g. Th2- or Th-17 cell mediated
inflammation) might be the basis to guide the patients
individual therapy.
Therefore the identification of VOCs, which are specif-
ically related to the expression of certain genes and pro-
teins is one important step in the future, which could be
helpful for the identification of discrete pathogenic path-
ways specific for asthma endotypes.
Additional file
Additional file 1: Table S1. Identified chemical VOC structures.
Table S2. Second possibility of cluster analysis. Figure S1. Discriminant
analyses for asthma clusters.
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